| Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells JJ Pen, BD Keersmaecker, C Heirman, J Corthals, T Liechtenstein, ... Gene therapy 21 (3), 262-271, 2014 | 101 | 2014 |
| Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity K Van der Jeught, PT Joe, L Bialkowski, C Heirman, L Daszkiewicz, ... Oncotarget 5 (20), 10100, 2014 | 85 | 2014 |
| Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer I Dufait, JK Schwarze, T Liechtenstein, W Leonard, H Jiang, D Escors, ... Oncotarget 6 (14), 12369, 2015 | 79 | 2015 |
| A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice T Liechtenstein, N Perez-Janices, M Gato, F Caliendo, G Kochan, ... Oncotarget 5 (17), 7843, 2014 | 74 | 2014 |
| Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy T Liechtenstein, I Dufait, A Lanna, K Breckpot, D Escors Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Formerly …, 2012 | 65 | 2012 |
| PD-L1/PD-1 co-stimulation, a brake for T cell activation and a T cell differentiation signal T Liechtenstein, I Dufait, C Bricogne, A Lanna, J Pen, K Breckpot, ... Journal of clinical & cellular immunology, 2012 | 63 | 2012 |
| A core of kinase-regulated interactomes defines the neoplastic MDSC lineage M Gato-Cañas, XM de Morentin, I Blanco-Luquin, J Fernandez-Irigoyen, ... Oncotarget 6 (29), 27160, 2015 | 59 | 2015 |
| Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of … T Liechtenstein, N Perez-Janices, I Blanco-Luquin, C Goyvaerts, ... Oncoimmunology 3 (7), e945378, 2014 | 55 | 2014 |
| Lentiviral vectors for cancer immunotherapy and clinical applications T Liechtenstein, N Perez-Janices, D Escors Cancers 5 (3), 815-837, 2013 | 55 | 2013 |
| Retroviral and lentiviral vectors for the induction of immunological tolerance I Dufait, T Liechtenstein, A Lanna, C Bricogne, R Laranga, A Padella, ... Scientifica 2012, 2012 | 51 | 2012 |
| Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells? D Escors, T Liechtenstein, N Perez-Janices, J Schwarze, I Dufait, ... Oncoimmunology 2 (10), e26148, 2013 | 33 | 2013 |
| Immune modulation by genetic modification of dendritic cells with lentiviral vectors T Liechtenstein, N Perez-Janices, C Bricogne, A Lanna, I Dufait, ... Virus research 176 (1-2), 1-15, 2013 | 28 | 2013 |
| Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis N Perez-Janices, I Blanco-Luquin, N Torrea, T Liechtenstein, D Escors, ... Oncotarget 6 (27), 23944, 2015 | 26 | 2015 |
| Targeted lentiviral vectors: current applications and future potential C Goyvaerts, T Liechtenstein, C Bricogne, D Escors, K Breckpot Gene Therapy-Tools and Potential Applications, 2013 | 22 | 2013 |
| Lentiviral vectors in immunotherapy I Dufait, T Liechtenstein, A Lanna, R Laranga, A Padella, C Bricogne, ... Gene Therapy-Tools and Potential Applications, 2013 | 9 | 2013 |
| Inmunoterapia genética con células dendríticas para el tratamiento del cáncer M Gato, T Liechtenstein, I Blanco-Luquín, MI Zudaire, G Kochan, D Escors Anales del Sistema Sanitario de Navarra 38 (2), 279-287, 2015 | 5 | 2015 |
| Manipulating immune regulatory pathways to enhance T cell stimulation JJ Pen, JL Aerts, T Liechtenstein, D Escors, K Breckpot Immune response activation, 2014 | 5 | 2014 |
| Critical mass hypothesis of T-cell responses and its application for the treatment of T-cell lymphoma C Bricogne, R Laranga, A Padella, I Dufait, T Liechtenstein, K Breckpot, ... Hodgkin’s and T-cell lymphoma: Diagnosis, Treatment Options and Prognosis …, 2012 | 5 | 2012 |
| Lentivector-based cancer immunotherapy silencing PD-L1 and modulating cytokine priming; development of ex vivo myeloid-derived suppressor cells to assess therapeutic efficacy. TM Liechtenstein UCL (University College London), 2015 | 2 | 2015 |
| Dendritic cells in cancer immunotherapy M Gato, T Liechtenstein, I Blanco-Luquín, MI Zudaire, G Kochan, D Escors Anales del sistema sanitario de Navarra 38 (2), 279-287, 2015 | 2 | 2015 |
